Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06667141 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
A Phase 1 study of Specific Advanced Solid Tumors, sponsored by Acrivon Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 15
- Study locations
NCT06667141 is a Phase 1 study of Specific Advanced Solid Tumors that is actively recruiting participants, run by Acrivon Therapeutics. The registered enrollment target is 100 participants. The trial reports 15 study locations across 12 states.
The verdict
NCT06667141, a Phase 1 study of Specific Advanced Solid Tumors, is actively recruiting participants, sponsored by Acrivon Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a first in-human, Open-label Phase 1 study to assess the safety of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.
Conditions Studied
Interventions
- DRUG ACR-2316
Study Locations (15)
California
- Precision NextGen Oncology & Research Center - Beverly Hills
- Hoag Memorial Hospital Presbyterian - Newport Beach
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
- Montefiore Medical Centre - The Bronx
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- NEXT Oncology - San Antonio
Arizona
- HonorHealth Research Institute - Phoenix
Colorado
- Denver Health One - Denver
Florida
- Florida Cancer Specialist - Sarasota
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-10-08 |
| Est. Completion | 2026-12-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06667141
The ClinicalTrials.gov registry entry for NCT06667141 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acrivon Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Specific Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which ACR-2316 is the first listed.
NCT06667141 reports 15 study locations spanning 12 distinct geographic areas - top geographies include California, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT06667141 about?
NCT06667141 is a clinical study titled "Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors". This is a first in-human, Open-label Phase 1 study to assess the safety of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.
What is the current status of trial NCT06667141?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2024-10-08. Estimated completion is 2026-12-12.
What conditions does trial NCT06667141 study?
This clinical trial studies the following conditions: Specific Advanced Solid Tumors.
What interventions are being tested in trial NCT06667141?
The interventions under investigation include: ACR-2316 (DRUG).
Who is sponsoring clinical trial NCT06667141?
This trial is sponsored by Acrivon Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06667141 being conducted?
This trial has 15 study locations across Arizona, California, Colorado, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.